Citadel Advisors’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Citadel Advisors’s Portfolio OSIR Stock Details OSIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-15,242	Closed	-$75K	–	8577
2016 Q4	$75K	Buy	+15,242	New	+$78.1K	﹤0.01%	6775
2016 Q1	–	Sell	-27,350	Closed	-$191K	–	9264
2015 Q4	$283K	Buy	+27,350	New	+$371K	﹤0.01%	5301
2015 Q3	–	Sell	-20,330	Closed	-$392K	–	9717
2015 Q2	$396K	Sell	20,330 -107,038	-84%	-$1.89M	﹤0.01%	5332
2015 Q1	$2.24M	Buy	127,368 +107,746	+549%	+$1.81M	﹤0.01%	2923
2014 Q4	$314K	Sell	19,622 -11,542	-37%	-$155K	﹤0.01%	5362
2014 Q3	$392K	Buy	31,164 +12,836	+70%	+$183K	﹤0.01%	4938
2014 Q2	$287K	Sell	18,328 -9,639	-34%	-$142K	﹤0.01%	5112
2014 Q1	$367K	Sell	27,967 -5,951	-18%	-$93.1K	﹤0.01%	4775
2013 Q4	$545K	Buy	33,918 +27,045	+393%	+$431K	﹤0.01%	3919
2013 Q3	$114K	Sell	6,873 -17,977	-72%	-$266K	﹤0.01%	5257
2013 Q2	$251K	Buy	+24,850	New	+$261K	﹤0.01%	4461

Other funds holding OSIR

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's OSIR Position: Q1 2017 in Review

Citadel Advisors sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2017, closing a stake of 15,242 shares — an estimated $75K sold.

Citadel Advisors first reported a position in OSIR in Q2 2013 and held it in 11 quarters. The position peaked at $2.24M in Q1 2015. 11 funds tracked by Wall St. Rank hold OSIR as of Q1 2017.

Citadel Advisors reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Citadel Advisors sold 15,242 Osiris Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $75K.
Citadel Advisors first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
Citadel Advisors's Osiris Therapeutics, Inc. Common Stock position peaked at $2.24M in Q1 2015.
11 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.